Pharmacokinetics of amlodipine in renal impairment

Eur J Clin Pharmacol. 1989;36(2):205-8. doi: 10.1007/BF00609197.


Amlodipine was administered as 14 single 5-mg oral daily doses to 27 male subjects with renal function ranging from normal to haemodialysis-dependent. Blood specimens were obtained for measurement of plasma amlodipine concentrations for 24 h following the first dose, for 168 h following the final dose and during daily administration of amlodipine. Amlodipine was well tolerated. Renal impairment had little effect on the pharmacokinetics of amlodipine. The elimination half-life was of the order of 50 h, similar to previously reported values and did not vary with renal function. Steady-state pre-dose concentrations were observed after the ninth dose. Accumulation of amlodipine was not significantly different from that expected on theoretical grounds and did not significantly change with renal function. These results suggest that once daily administration of amlodipine is suitable for all degrees of renal function and that dosage adjustment is not necessary in renal impairment.

MeSH terms

  • Adult
  • Aged
  • Amlodipine
  • Calcium Channel Blockers / adverse effects
  • Calcium Channel Blockers / pharmacokinetics*
  • Female
  • Half-Life
  • Humans
  • Kidney Diseases / metabolism*
  • Male
  • Middle Aged
  • Nifedipine / adverse effects
  • Nifedipine / analogs & derivatives*
  • Nifedipine / pharmacokinetics


  • Calcium Channel Blockers
  • Amlodipine
  • Nifedipine